Suppression of neuropathic pain by a naturally-derived peptide with NMDA antagonist activity

Julie B. Siegan, Aldric T. Hama, Jacqueline Sagen

Research output: Contribution to journalArticlepeer-review

33 Scopus citations

Abstract

Chronic pain may result from hyperexcitability following activation of spinal NMDA receptors. A naturally-derived mammalian peptide, histogranin, may possess NMDA antagonist activity. This study explored the possibility that stable analog [Ser1]Histogranin (SHG) could reduce chronic pain. Neuropathic pain was induced using the chronic constriction injury model (CCI). Intrathecal injection of SHG markedly attenuated the hyperalgesia and allodynia resulting from CCI, nearly normalizing responses. These results suggest that the natural peptide histogranin may be a novel adjunct in neuropathic pain management.

Original languageEnglish (US)
Pages (from-to)331-334
Number of pages4
JournalBrain Research
Volume755
Issue number2
DOIs
StatePublished - May 2 1997
Externally publishedYes

Keywords

  • adrenal medulla
  • chronic pain
  • N-methyl-D-aspartate (NMDA) receptor
  • neuropeptide
  • peripheral neuropathy
  • spinal cord

ASJC Scopus subject areas

  • Neuroscience(all)

Fingerprint Dive into the research topics of 'Suppression of neuropathic pain by a naturally-derived peptide with NMDA antagonist activity'. Together they form a unique fingerprint.

Cite this